Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + Nifurtimox + Topotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Nifurtimox||Lampit|BAY 2502|BAYER 2502||Nifurtimox is an anti-protozoan drug typically used to treat Chagas disease, however, it has been also show to inhibit the growth of tumor cells, with preferential efficacy in a hypoxic environment (PMID: 28560059, PMID: 31260646).|
|Topotecan||Hycamtin||Topotecan Hcl||Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT00601003||Phase II||Cyclophosphamide + Nifurtimox + Topotecan||Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma||Active, not recruiting||USA||0|